Travere Therapeutics (NASDAQ:TVTX – Get Free Report) was upgraded by equities research analysts at Guggenheim from a “neutral” rating to a “buy” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage presently has a $25.00 price objective on the stock. Guggenheim’s target price would suggest a potential upside of 94.70% from the [...]
Related by source
-
New Zealand Moves to Change Law After Uber Loses Contractor Case
-
Thai State Fund Seeks $4.5 Billion to Help Boost Stock Market
-
FBI Says Trump Was Subject of Apparent Assassination Attempt: AP
-
Trump Is Safe After Apparent Assassination Attempt in Florida
-
Extraprofitti, La Russa risponde a Tajani: “Non serve inalberarsi”
-
What Fed Rate Cuts Mean to Finance Chiefs
-
SMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Super Micro Computer, Inc....
-
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Inve...
-
Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote
-
Gunshots Heard Near Trump’s Golf Course, No Injuries Reported
-
Fed Ready to Unshackle US Economy With Soft Landing at Stake
-
Mathias Döpfner, KKR Said to Near Deal on Axel Springer Split
